Stockscreener 앱 받기
1.52
1.30%
-0.02
시간 외 거래:
1.52
전일 마감가:
$1.54
열려 있는:
$1.55
하루 거래량:
31,356
Relative Volume:
0.04
시가총액:
$74.70M
수익:
$134.60K
순이익/손실:
$-11.81M
주가수익비율:
-6.3097
EPS:
-0.2409
순현금흐름:
$-10.05M
1주 성능:
+0.66%
1개월 성능:
-1.94%
6개월 성능:
+14.29%
1년 성능:
-27.62%
1일 변동 폭
$1.52
$1.5543
1주일 범위
$1.48
$1.57
52주 변동 폭
$1.13
$2.2364
Medicinova Inc Stock (MNOV) Company Profile
명칭
Medicinova Inc
전화
858-373-1500
주소
4275 EXECUTIVE SQUARE, LA JOLLA, CA
MNOV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.52 | 75.69M | 134.60K | -11.81M | -10.05M | -0.2409 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-10 | 개시 | Maxim Group | Buy |
| 2019-03-25 | 재개 | B. Riley FBR | Buy |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 개시 | Credit Suisse | Outperform |
| 2013-01-04 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-05-24 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2011-10-18 | 재확인 | MLV Capital | Buy |
| 2011-06-22 | 개시 | Global Hunter Securities | Buy |
| 2010-05-12 | 개시 | Wedbush | Outperform |
| 2008-11-12 | 재확인 | Ladenburg Thalmann | Buy |
| 2008-05-15 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 개시 | Punk, Ziegel & Co | Buy |
모두보기
Medicinova Inc 주식(MNOV)의 최신 뉴스
MediciNova (NASDAQ:MNOV) Receives “Buy” Rating from D. Boral Capital - Defense World
MediciNova (MNOV) Analyst Rating Maintained at 'Buy' with $9.00 - GuruFocus
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
MediciNova completes enrollment in phase 2b/3 ALS clinical trial - Investing.com
MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative
MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND - Sahm
Is MediciNova Inc a good long term investmentTake Profit Strategies & Ride the Wave of Market-Beating Growth - earlytimes.in
Gainers Report: Can MediciNova Inc stock continue upward trendShare Buyback & Growth Focused Investment Plans - BỘ NỘI VỤ
Can MediciNova Inc. stock sustain free cash flow growthMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
EBITDA per share of MediciNova, Inc. – TSE:4875 - TradingView
Can MediciNova Inc. stock continue upward trendJuly 2025 Price Swings & Verified Entry Point Signals - Newser
MediciNova (MNOV) Stock Analysis Report | Financials & Insights - Benzinga
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
MediciNova, Inc. (MNOV) 9.22% in After-hours: Amid Routine Trading - Stocks Telegraph
MediciNova Reports Significant Milestone in MN-001 Program Following Journal Publication on Cholesterol Efflux Mechanism - Quiver Quantitative
Message from the CEO to MediciNova Shareholders - GlobeNewswire
MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ - MSN
Stocks of Medicinova Inc (MNOV) are poised to climb above their peers - Setenews
Is MediciNova Inc. stock attractive for growth ETFsPortfolio Gains Summary & Risk Controlled Swing Alerts - BỘ NỘI VỤ
Why MediciNova Inc. stock could benefit from AI revolutionWeekly Gains Summary & Entry Point Strategy Guides - moha.gov.vn
Market Moves: Why MediciNova Inc. stock could benefit from AI revolutionAnalyst Downgrade & Verified Entry Point Signals - BỘ NỘI VỤ
MediciNova (NASDAQ:MNOV) Stock Price Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Can MediciNova Inc. stock attract ESG capital inflowsPortfolio Return Summary & Weekly Stock Breakout Alerts - newser.com
Can MediciNova Inc. stock beat market expectations this quarterCPI Data & Weekly Breakout Stock Alerts - newser.com
Will MediciNova Inc. stock continue upward momentumJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Trend analysis for MediciNova Inc. this weekJuly 2025 Breakouts & AI Driven Stock Price Forecasts - newser.com
Will MediciNova Inc. stock maintain growth story2025 Top Decliners & Daily Profit Focused Screening - newser.com
What Fibonacci levels say about MediciNova Inc. reboundWeekly Trade Summary & Real-Time Sentiment Analysis - newser.com
What dividend safety score for MediciNova Inc. stockShort Setup & Real-Time Chart Breakout Alerts - newser.com
Is MediciNova Inc. stock a contrarian buy2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Applying big data sentiment scoring on MediciNova Inc.2025 Key Highlights & Smart Swing Trading Alerts - newser.com
MediciNova appoints former FDA official as clinical advisor By Investing.com - Investing.com Nigeria
MediciNova appoints former FDA official as clinical advisor - Investing.com
Medicinova Inc (MNOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):